VU, VUMC Research Funding Surpasses $1 Billion

Apr 11, 2022 at 09:28 am by Staff


by Marissa Shapiro

Scholars at Vanderbilt University and Vanderbilt University Medical Center achieved a significant milestone in 2021: more than $1 billion in research funding awarded from external organizations.

Vanderbilt’s global leadership in research — from biomedical and biotechnology discoveries to vaccine development to groundbreaking advances in computer science, education and psychology — contributed to this landmark achievement, reflecting the University and Medical Center’s continued growth as leading research organizations.

“Vanderbilt researchers are among the most accomplished in the world, contributing in significant ways to solving the most complex scientific and medical challenges of today, while also charting important new pathways of discovery for tomorrow,” said Chancellor Daniel Diermeier. “Reaching this funding benchmark affirms Vanderbilt’s place among the world’s foremost research institutions and inspires new levels of aspiration as we look ahead to the future.”

Together in fiscal 2021, Vanderbilt and VUMC received more than 3,100 external awards totaling $1,090,386,890. Awards include those from the National Institutes of Health, the National Science Foundation, the Department of Defense, the Department of Education and the Centers for Disease Control and Prevention.

“This milestone marks Vanderbilt’s world-class academic achievements and also positions us to make even more quantum leaps in research going forward,” said C. Cybele Raver, provost and vice chancellor for Academic Affairs. “I commend the powerhouse faculty, postdoctoral fellows and students whose ambition and hard work have gotten us here.”

Research funded during this year has supported numerous projects that already are benefiting society. Results include evidence-based improvements to classrooms and major roadways, positive momentum toward new drug targets for treating devastating diseases, changing national health guidelines and using advanced computational approaches to pursue new foundational knowledge about the human body.

“This unprecedented level of external research funding recognizes the extraordinary productivity, creativity and commitment of our scientists, their staff and our entire research community even in the middle of the worst pandemic in more than 100 years,” said Jeff Balser, MD, PhD, President and CEO of VUMC and Dean of Vanderbilt University School of Medicine. “I am extremely proud of and grateful for what they have achieved — and continue to achieve — for the betterment of human health in the United States and throughout the world.”

These projects include:

A grant from the Defense Advanced Research Projects Agency funded Crowe’s efforts to develop a fully integrated pipeline for ultra-rapid discovery of pathogens, their protective antigens and development of fully human antibody therapeutics. Typically, pathogen discovery techniques span disciplines — from large-scale growth of live pathogens to rapid manufacture of antibody genes — that all require unique expertise and protocols. The Crowe lab’s potent human antibodies, with their rapid delivery within the body by an RNA nanoparticle mechanism, have potential to revolutionize how antiviral interventions are conducted, especially in outbreak emergencies like COVID-19.

Crowe’s lab also worked on a universal influenza vaccine through research funded by the National Institutes of Allergy and Infectious Diseases within the National Institute of Health. The multidisciplinary group working on this project will develop new virus structure-based models that run computational tests on neutralizing influenza. This work is connected to Crowe’s ambitious Ahead100 program, which aims to prevent future disease outbreaks from becoming pandemics by using monoclonal antibodies as the critical stopgap between diagnosis and vaccine readiness.

“The pioneering and collaborative spirit of our expert investigators and multi-disciplinary teams have made this achievement possible. However, our most significant impact cannot be measured by levels of research funding. Rather, as a team, we have improved and lengthened the lives of people diagnosed with diseases worldwide through the discoveries made possible by this extramural support,” said Jennifer Pietenpol, PhD, Benjamin F. Byrd Jr. Professor of Oncology and VUMC Chief Scientific and Strategy Officer. “In addition, generous philanthropic gifts over many years have provided, and will continue to provide, the seed and transformative funding to launch many of the projects that are now funded by federal, foundation, pharmaceutical and biotech sources.”

Sections: Business/Tech